Lysophosphatidylcholine regulates synthesis of biglycan and the proteoglycan form of macrophage colony stimulating factor

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 5, 2003, Pages 809-815

  Chang, Mary Y ^a   Tsoi, Christina ^b   Wight, Thomas N ^b   Chait, Alan ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b HOPE HEART INSTITUTE   (United States)

Author keywords

Biglycan; Lysophosphafidylcholine; Oxidized LDL; Proteoglycan; Proteoglycan form of macrophage colony stimulating factor

Indexed keywords

7 OXOCHOLESTEROL; 7BETA HYDROXYCHOLESTEROL; BIGLYCAN; COLONY STIMULATING FACTOR 1; CORE PROTEIN; DECORIN; LIPOPROTEIN; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDYLCHOLINE; OXIDIZED LOW DENSITY LIPOPROTEIN; OXYSTEROL; PROTEOGLYCAN; VERSICAN;

ANIMAL CELL; ARTERY MUSCLE; ARTICLE; ATHEROGENESIS; CARBOHYDRATE SYNTHESIS; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION REGULATION; LIPID COMPOSITION; MACACA; MACROPHAGE; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SYNTHESIS; PROTEOGLYCAN SYNTHESIS; REGULATORY MECHANISM; SMOOTH MUSCLE FIBER;

ANIMALS; CELLS, CULTURED; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION REGULATION; HYDROXYCHOLESTEROLS; KETOCHOLESTEROLS; LIPOPROTEINS, LDL; LYSOPHOSPHATIDYLCHOLINES; LYSOPHOSPHOLIPIDS; MACACA NEMESTRINA; MACROPHAGE COLONY-STIMULATING FACTOR; MOLECULAR WEIGHT; MUSCLE, SMOOTH, VASCULAR; PROTEIN ISOFORMS; PROTEOGLYCANS;

EID: 0037963942     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000069208.20268.D0     Document Type: Article

References (40)

1. Camejo G, Camejo EH, Olsson U, Bondjers G. Proteoglycans and lipoproteins in atherosclerosis. Curr Opin Lipidol. 1993;4:385-391.
2. Galis ZS, Alavi MZ, Moore S. Co-localization of apolipoprotein B and chondroitin sulfate in an injury model from human atherosclerotic lesions. Am J Pathol. 1993;142:1432-1438.
3. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995;15:551-561.
4. Saxena U, Klein MG, Vanni TM, Goldberg IJ. Lipoprotein lipase increases low density lipoprotein retention by subendothelial cell matrix. J Clin Invest. 1992;89:373-380.
5. Olin KL, Potter-Perigo S, Barrett HR, Wight TN, Chait A. Lipoprotein lipase enhances the binding of native oxidized low density lipoproteins to versican and biglycan synthesized by cultured arterial smooth muscle cells. J Biol Chem. 1999;274:34629-34636.
6. Hurt-Camejo E, Camejo G, Rosengren B, Lopez F, Ahlstrom C, Fager G, Bondjers G. Effect of arterial proteoglycans and glycosaminoglycans on low density lipoprotein oxidation and its uptake by human macrophages and arterial smooth muscle cells. Arterioscler Thromb. 1992;12:569-583.
7. Vijayagopal P, Srinivasan SR, Jones KM, Radhakrishnamurthy B, Berenson GS. Complexes of low-density lipoproteins and arterial proteoglycan aggregates promote cholesteryl ester accumulation in mouse macrophages. Biochim Biophys Acta. 1985;837:251-261.
8. Wight TN. The vascular extracellular matrix. In: Fuster V, Ross R, Topol E, eds. Atherosclerosis and Coronary Artery Disease. Philadelphia: Lippincott-Raven; 1996:421-440.
9. Kovanen PT, Pentikainen MO. Decorin links low-density lipoproteins (LDL) to collagen: a novel mechanism for retention of LDL in the atherosclerotic plaque. Trends Cardiovasc Med. 1999;9:86-91.
10. O'Brien KD, Olin KL, Alpers CE, Chiu W, Ferguson M, Hudkins K, Wight TN, Chait A. Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. Circulation. 1998;98:519-527.
11. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:1876-1890.
12. Chang MY, Olin KL, Tsoi C, Wight TN, Chait A. Human monocytederived macrophages secrete two forms of proteoglycan-macrophage colony stimulating factor (PG-MCSF) that differ in their ability to bind low density lipoproteins. J Biol Chem. 1998;273:15985-15992.
13. Suzu S, Inaba T, Yanai N, Kawashima T, Yamada N, Oka T, Machinami R, Ohtsuki T, Kimura F, Kondo S, et al. Proteoglycan form of macrophage colony-stimulating factor binds low density lipoprotein. J Clin Invest. 1994;94:1637-1641.
14. 1 on the synthesis of a large versican-like chondroitin sulfate proteoglycan by arterial smooth muscle cells. J Biol Chem. 1991;66:17640-17647.
15. 1 differentially affect the synthesis of biglycan and decorin by monkey arterial smooth muscle cells. Arterioscler Thromb. 1993;13:1026-1036.
16. Edwards IJ, Xu H, Wright MJ, Wagner WD. Interleukin-1 upregulates decorin production by arterial smooth muscle cells. Arterioscler Thromb. 1994;14:1032-1039.
17. Chang MY, Potter-Perigo S, Tsoi C, Chait A, Wight TN. Oxidized low density lipoproteins regulate synthesis of monkey aortic smooth muscle cell proteoglycans that have enhanced native low density lipoprotein binding properties. J Biol Chem. 2000;275:4766-4773.
18. Brown BG, Zhao X-Q, Sacco DE, Albers JJ. Atherosclerosis regression, plaque disruption, and cardiovascular events: a rationale for lipid lowering in coronary artery disease. Ann Rev Med. 1993;44:365-376.
19. Murugesan G, Fox PL. Role of lysophosphatidylcholine in the inhibition of endothelial cell motility by oxidized low density lipoprotein. J Clin Invest. 1996;97:2736-2744.
20. Heinecke JW, Baker L, Rosen H, Chait A. Superoxide-mediated free radical modification of low density lipoprotein by arterial smooth muscle cells. J Clin Invest. 1986;77:757-761.
21. Chait A, Henze K, Mazzone T, Jensen M, Hammond W. Low density lipoprotein receptor activity in freshly isolated human blood monocytes. Metab Clin Exper. 1982;31:721-727.
22. Fleischmajer R, Fisher LW, MacDonald ED, Jacobs LJ, Perlish JS, Termine JD. Decorin interacts with fibrillar collagen of embryonic and adult human skin. J Struct Biol. 1991;106:82-90.
23. Partenheimer A, Schwarz K, Wrocklage C, Kolsch E, Kresse H. Proteoglycan form of colony-stimulating factor-1 (proteoglycan-100): stimulation of activity by glycosaminoglycan removal and proteolytic processing. J lmmunol. 1995;155:5557-5565.
24. Fisher LW, Termine JD, Young MF. Deduced protein sequence of bone small proteoglycan I (biglycan) shows homology with proteoglycan (decorin) and several nonconnective tissue proteins in a variety of species. J Biol Chem. 1989;264:4571-4576.
25. Camejo G, Fager G, Rosengren B, Hurt-Camejo E, Bondjers G. Binding of low density lipoproteins by proteoglycans synthesized by proliferating and quiescent human arterial smooth muscle cells. J Biol Chem. 1993; 268:14131-14137.
26. Jarvelainen HT, Kinsella MG, Wight TN, Sandell LJ. Differential expression of small chondroitin/dermatan sulfate proteoglycans. PG-I/biglycan and PG-II/decorin, by vascular smooth muscle and endothelial cells in culture. J Biol Chem. 1991;266:23274-23281.
27. Cader A, Steinberg FM, Mazzone T, Chait A. Mechanisms of enhanced macrophage apo E secretion by oxidized LDL. J Lipid Res. 1997;38: 981-991.
28. Bartlett GR. Phosphorus assay in column chromatography. J Biol Chem. 1959;234:466-468.
29. Marathe GK, Silva AR, de Castro Faria Neto HC, Tjoelker LW, Prescott SM, Zimmerman GA, McIntyre TM. Lysophosphatidycholine and lyso-PAF display PAF-like activity derived from contaminating phospholipids. J Lipid Res. 2001;42:1430-1437.
30. Wateson A, Uthne K, Westermark B. A novel assay for the biosynthesis of sulphated polysaccharide and its application to studies on the effects of somatomedin on cultured cells. Biochem J. 1973;136:1069-1074.
31. Cardoso L, Maurao PAS. Glycosaminoglycan fractions from human arteries presenting diverse susceptibilities to atherosclerosis have different binding affinities to plasma low density lipoprotein. Arterioscler Thromb. 1994;14:115-124.
32. Brown AJ, Jessup W. Oxysterols and atherosclerosis. Atherosclerosis. 1999;142:1-28.
33. McIntyre TM, Zimmerman GA, Prescott SM. Biologically active oxidized phospholipids. J Biol Chem. 1999;274:189-192.
34. Subbaiah PV, Chen CH, Bagdade JD, Albers JJ. Substrate specificity of plasma lysolecithin acyltransferase and the molecular species of lecithin formed by the reaction. J Biol Chem. 1985;260:5308-5314.
35. Portman OW, Alexander M. Lysophosphatidylcholine concentrations and metabolism in aortic intima plus inner media: effect of nutritionally induced atherosclerosis. J Lipid Res. 1969;10:158-165.
36. Hollman J, Thiel J, Schmidt A, Buddecke E. Increased activity of chondroitin sulfate-synthesizing enzymes during proliferation of arterial smooth muscle cells. Exp Cell Res. 1986;167:484-494.
37. Weltzien HU. Cytolytic and membrane-perturbing properties of lysophosphatidycholine. Biochim Biophys Acta. 1979;559:259-287.
38. Takeda A, Palfree R, Forsdyke D. Role of serum in inhibition of cultured lymphocytes by lysophosphatidylcholine. Biochem Biophys Acta. 1982; 710:87-98.
39. Kikuchi A, Tomoyasu H, Kido I, Takahashi K, Tanaka A, Nonaka I, Iwakami N, Kamo I. Haemopoietic biglycan produced by brain cells stimulates growth of microglial cells. J Neuroimmunol. 2000;106:78-86.
40. Stanley ER, Guilbert LJ, Tushinski RJ, Bartelmez SH. CSF-1: a mononuclear phagocyte lineage-specific hemopoietic growth factor. J Cell Biochem. 1983;21:151-159.